Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 18,984	$ 27,007
Restricted cash equivalents	500	500
Marketable securities	67,803	71,475
Prepaid expenses and other current assets	1,751	1,942
Total current assets	89,038	100,924
Property and equipment, net	5,985	6,038
Operating lease right-of-use assets	1,423	1,065
Total assets	96,446	108,027
Current liabilities:
Accounts payable	1,511	1,460
Accrued expenses and other current liabilities	2,716	2,349
Operating lease liability, current portion	923	1,006
Total current liabilities	5,150	4,815
Operating lease liability, less current portion	500	59
Long-term debt	29,207	29,149
Total liabilities	34,857	34,023
Commitments and contingencies (Note 10)
Stockholders' equity / members' deficit:
Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of March 31, 2023 and December 31, 2022	0	0
Additional Paid in Capital	78,018	75,842
Accumulated other comprehensive loss	(10)	(73)
Accumulated deficit	(47,291)	(38,919)
Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc.	30,722	36,855
Non-controlling interest	30,867	37,149
Total stockholders' equity	61,589	74,004
Total liabilities and stockholders' equity	96,446	108,027
Common Class A [Member]
Stockholders' equity / members' deficit:
Common stock, value	3	3
Common Class B [Member]
Stockholders' equity / members' deficit:
Common stock, value	2	2
Common Class C [Member]
Stockholders' equity / members' deficit:
Common stock, value	$ 0	$ 0